Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Posted: 8 May 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its…
BioMelbourne Network appoints new CEO
Posted: 7 May 2024 BioMelbourne Network, the peak body in the Victorian healthtech industry, is excited to announce the appointment of Karen Parr, as its incoming Chief Executive Officer. Karen has extensive experience leading complex science-based policy and…
New industry-research partnership accelerates Medtech innovation in Melbourne
Posted: 7 May 2024 Australian medical device company Signature Orthopaedics is partnering with leading Medtech researchers at the University of Melbourne and RMIT University. The three-way strategic partnership connects research excellence in the fields of biomedical engineering, health,…
A $411 million commitment for researchers to bring their discoveries to life
Posted: 6 May 2024 The National Health and Medical Research Council (NHMRC) continues to invest in our nation’s health and medical research sector, with over $411 million awarded to 229 outstanding researchers to investigate Australia’s greatest health challenges.…
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Posted: 6 May 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces initial encouraging data from EFTISARC-NEO, a Phase II investigator-initiated…
DIMERIX RECEIVES APPROVAL FOR PAEDIATRIC INVESTIGATION PLAN FROM THE UK MHRA
Posted: 6 May 2024 Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Paediatric Investigation Plan (PIP) for…
One-two punch treatment delivers blood cancer knockout
Posted: 6 May 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
Trofinetide New Drug Submission for Rett Syndrome Accepted for Priority Review by Health Canada
Posted: 1 May 2024 Neuren Pharmaceuticals (ASX: NEU) is pleased to report that Health Canada has accepted for review the New Drug Submission (NDS) of trofinetide for the treatment of Rett syndrome, that was submitted by Neuren’s global…
COMPLETION OF EYE AND EAR REDEVELOPMENT A TRUE VISION
Posted: 1 May 2024 The redevelopment of Australia’s only specialist eye, ear, nose and throat hospital is now complete, with the world class specialist health, research and education facility bigger and better than before. Minister for Health Infrastructure…
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Posted: 1 May 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434…
Vic sees 34% increase in digital health startups
Posted: 1 May 2024 Victoria has seen a 34% increase in digital health startups in the past year, according to the latest data from commercialisation firm ANDHealth. Investment and support from the Victorian Government for digital health programs like LaunchVic,…
Funding success accelerating cardiovascular research
Posted: 1 May 2024 More than $800,000 in seed funding has been awarded to four Monash Victorian Heart Institute partnered research teams in Round 1 of the Australian Stroke and Heart Research Accelerator (ASHRA) Seed Funding Scheme. The ASHRA Centre…
